Annual Report 2019
Department of Pharmacy
Toshikatsu Kawasaki, Takahiro Nishimura, Reiko Matsui, Masahito Yonemura, Norio Goto, Daisuke Kano, Naoko Kumazawa, Shinya Suzuki, Nobuo Mochizuki, Yuko Ishikawa, Kenji Kawasumi, Shinichi Masuda,Tomoko Morita, Yoshiko Ishihara, Ayumi Komuro, Chihiro Nakada, Yoshihiro Iwamoto, Sayaka Nakajima, Misaki Takeno, Nobue Sato, Yoshiyuki Sano, Daisuke Hisamatsu, Akiko Abe, Masaki Tanaka, Kanako Mamishin, Takashi Igarashi, Tsuyoshi Uemoto, Hayato Kamata, Wataru Suenaga, Hidetaka suzuki, Yumiko Seto, Ken Demachi, Asumi Kaneko, Junko Tauchi
Introduction
The main objectives of the Department of Pharmacy are: (1) To promote clinical studies to create new evidence-based data; (2) To provide chemotherapy based on the most updated evidence-based data; and (3) To pursue patient-centered pharmaceutical care.
Our residents’ training program started in 2006. In 2019, five residents joined our department. Presently, we have a total of 18 residents. In addition, our department has accepted six trainees from other institutions for our oncology pharmacist training programs in 2019. Through 2019, we educated two pharmacy students.
The Department of Pharmacy provides various important services: controlling inventory, dispensing medications, preparing i.v. solutions for chemotherapy, which includes the aseptic mixing of antineoplastic agents, collecting and providing drug information, managing therapeutic drug monitoring, checking treatment regimens for each patient’s chemotherapy, and providing pharmaceutical management and counseling.
Our department reviews the drugs taken by patients before and during their hospitalization. In inpatient care, our department assigns pharmacists to provide medication counseling and drug information for healthcare providers and patients, to pursue effective pharmaceutical care. In outpatient care, our department provides a pharmacy outpatient service in which pharmacists check patients for adverse reactions and doses of antineoplastic agents, especially in the case of oral anticancer medications. We then assess the necessity of supportive-care medications and suggest them to physicians. The pharmacy outpatient service also reviews the drugs taken by all patients to evaluate when patients have to stop their anticoagulants before their operation or when they have to stop to take metformin before examinations with iodinated-contrast material. Pharmacists are on duty at the Outpatient Chemotherapy Center as dedicated staff members. The pharmacists provide a Chemotherapy Hotline Service, which is a direct line for our outpatients who have any problems concerning their chemotherapy treatment. In the Outpatient Chemotherapy Center, pharmacists are always available to provide drug information for healthcare providers and patients. We also manage investigational drugs.
Research activities
We have presented oral sessions and poster sessions 21 times at national and international academic conferences. In addition, 8 scientific papers were accepted for publication.
List of papers published in 2019
Journal
1. Demachi K, Bando H, Nomura H, Shitara K, Yoshino T, Yamaguchi M, Kawasaki T. Clinical impact of renal impairment on the safety and efficacy of S-1 plus oxaliplatin in patients with advanced gastric cancer: a single institutional study. Jpn J Clin Oncol, 50:129-137, 2020
2. Watanabe K, Mitsunaga S, Kojima M, Suzuki H, Irisawa A, Takahashi H, Sasaki M, Hashimoto Y, Imaoka H, Ohno I, Ikeda M, Akimoto T, Ochiai A. The “histological replacement growth pattern” represents aggressive invasive behavior in liver metastasis from pancreatic cancer. Cancer Med, 9:3130-3141, 2020
3. Nishimura T, Kohno H, Nagai H, Maruoka D, Koike Y, Kobayashi M, Atsuda K. The Population Pharmacokinetics of Rifampicin in Japanese Pulmonary Tuberculosis Patients. Drug Res (Stuttg), 70:199-205, 2020
4. Nomura H, Hatogai K, Maki Y, Mochizuki N, Tanaka M, Saito S, Daiko H, Kojima T, Kawasaki T. Risk factors for febrile neutropenia in neoadjuvant docetaxel, cisplatin, and 5-fluorouracil chemotherapy for esophageal cancer. Support Care Cancer, 28:1849-1854, 2020
5. Nomura H, Katakura N, Morita T, Sano Y, Usui H, Hiura S, Nakakuni M, Otsuka M, Akiyama E, Endo K. Surface contamination of the outer and blister packages of oral anticancer drugs: A multicenter study. J Oncol Pharm Pract, 26:141-145, 2020
6. Kamata H, Suzuki S, Demachi K, Suzuki H, Sugama Y, Ikegawa K, Igarashi T, Yamaguchi M, Okudera H, Tahara M, Kawasaki T. Drug cost savings resulting from the outpatient pharmacy services collaborating with oncologists at outpatient clinics. Eur J Oncol Pharm, 3:e22, 2020
7. Muraishi H, Enomoto R, Katagiri H, Kagaya M, Watanabe T, Narita N, Kano D. Visualization of Low-Level Gamma Radiation Sources Using a Low-Cost, High-Sensitivity, Omnidirectional Compton Camera. J Vis Exp, doi: 10.3791/60463, 2020
8. Horinouchi A, Suzuki S, Kamata H, Kaneko A, Tomohiro T, Fujisawa T, Ueda Y, Okao S, Kawasaki T, Tahara M. Grade 3 infusion-related reaction due to cetuximab administered with 5-fluorouracil and cisplatin chemotherapy for a recurrent and metastatic head and neck cancer patient who received chlorpheniramine 5 mg, dexamethasone 13.2 mg and aprepitant 125 mg premedication. Eur J Oncol Pharm, 3:e21, 2020
9. Demachi K, Suzuki S, Kamata H, Suzuki H, Sugama Y, Ikegawa K, Igarashi T, Yamaguchi M. Impact of outpatient pharmacy services collaborating with oncologists at an outpatient clinic for outpatient chemotherapy prescription orders. Eur J Oncol Pharm, 2:e10, 2019
10. Suzuki S, Uchida M, Suga Y, Sugawara H, Kokubun H, Uesawa Y, Nakagawa T, Takase H. A Nationwide Survey of Community Pharmacist Contributions to Polypharmacy in Opioid-Using and Non-using Cancer Patients in Japan. Biol Pharm Bull, 42:1164-1171, 2019
11. Uchida M, Kondo Y, Suzuki S, Hosohata K. Evaluation of Acute Kidney Injury Associated With Anticancer Drugs Used in Gastric Cancer in the Japanese Adverse Drug Event Report Database. Ann Pharmacother, 53:1200-1206, 2019
12. Sugawara H, Uchida M, Suzuki S, Suga Y, Uesawa Y, Nakagawa T, Takase H. Analyses of Respiratory Depression Associated with Opioids in Cancer Patients Based on the Japanese Adverse Drug Event Report Database. Biol Pharm Bull, 42:1185-1191, 2019
13. Uchida M, Suzuki S, Sugawara H, Suga Y, Kokubun H, Uesawa Y, Nakagawa T, Takase H. A nationwide survey of hospital pharmacist interventions to improve polypharmacy for patients with cancer in palliative care in Japan. J Pharm Health Care Sci, 5:14, 2019
14. Suga Y, Uchida M, Suzuki S, Sugawara H, Torigoe K, Futamura A, Uesawa Y, Nakagawa T, Takase H. Current Status of Adverse Events Related with Opioid Analgesics in Japan: Assessment Based on Japanese Adverse Drug Event Report Database. Biol Pharm Bull, 42:801-806, 2019